These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20008247)

  • 1. Pathogenesis and management of essential thrombocythemia.
    Beer PA; Green AR
    Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathogenesis and management of essential thrombocythaemia.
    Green AR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():36-9. PubMed ID: 10907463
    [No Abstract]   [Full Text] [Related]  

  • 5. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of essential thrombocythemia].
    Alvarez-Larrán A; Cervantes F; Besses C
    Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the myeloproliferative disorders : distinguishing data from dogma.
    Green AR; Vassiliou GS; Curtin N; Campbell PJ
    Hematol J; 2004; 5 Suppl 3():S126-32. PubMed ID: 15190294
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
    Tefferi A
    Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G; Barbui T
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of patients with essential thrombocythemia].
    Ramirez G; García-Sanchez R; Plaza S
    Med Clin (Barc); 2013 Mar; 140(6):278-82. PubMed ID: 23177312
    [No Abstract]   [Full Text] [Related]  

  • 14. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D; Mascarenhas J
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
    Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2020 Nov; 13(11):1189-1199. PubMed ID: 33076714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Landolfi R; Di Gennaro L
    Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
    Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
    Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population.
    Park SG; Ha JS
    Int J Lab Hematol; 2015 Aug; 37(4):e91-5. PubMed ID: 25630751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.